publication date: May. 8, 2020
NCI Trials
NCI Trials for May 2020
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase II – A071702
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma
Alliance for Clinical Trials in Oncology
Dunn, Gavin Peter
(314) 747-6141
Phase II – EAQ191
Cancer Therapy Risk-Reduction with Intensive Systolic BP Management (CARISMA) – a Phase II Study
ECOG-ACRIN Cancer Research Group
Ky, Bonnie
(215) 573-6606
Phase II – S1905
A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)
SWOG
Advani, Anjali S.
(216) 445-9354
Phase III – EA5181
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
ECOG-ACRIN Cancer Research Group
Pennell, Nathan Adam
(216) 445-9282
